A5342: Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

Study Location:

Baltimore

Topic:

HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02411539?term=A5342&rank=1

Coordinator:

Ilene Wiggins, RN

Enrollment:

Closed

Trial Period:

Completed

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01), in adults infected with HIV who are receiving antiretroviral therapy (ART).

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

410-614-2766

iwiggin1@jhmi.edu 

Categories

Location
Topic

Clinical Trials

A5345, Identification of Biomarkers to Predict Time to...

Brief Summary: The purpose of this study is to collect information about what happens when people pause, or temporarily stop...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More